Pathogenic bacterial contamination is a major threat to safety, human health, and ecosystems. Herein, we report an advantageous single-step, wash-free, and real-time bacterial detection platform operating with a single antibody. Escherichia coli was detected as a model analyte. This technology is based on graphene oxide-coated microplates (GOMs) and photoluminescent bioprobes (PLBs). On the one hand, using nonradiative energy transfer, GOMs are conceived to deactivate the photoluminescence of those PLBs that are not experimenting immunoreactions via antibody-bacterial membrane affinity. On the other hand, those PLBs experimenting immunoreactions preserve their photoluminescence because of both (i) the distance between the complex (PLBs-bacteria) and GOMs and (ii) the low affinity between the same complex and GOMs. With an optimal analytical performance of ∼30 min, the resulting bacterial detection platform was demonstrated to be fast and highly sensitive, exhibiting a limit of detection of ∼2 CFU mL–1. Industrial real samples were also successfully analyzed in a widely used format that is amenable to high-throughput applications. Moreover, the proposed technology is highly transformative, as graphene oxide is able to quench different fluorophores, and other analytes can be detected by simply changing the specific antibody.

No abstract

Serological tests are crucial in a pandemic scenario, since they are a valuable tool to spot those citizens with potential immunity, specific regions with herd immunity or particular at-risk populations, as well as acquired immunity after vaccination. Hence, high-throughput, fast, cost-effective, and straightforward technologies facilitating interrogation of COVID-19 seroconversion are an existing need. Herein, we developed an innovative assay for the determination of COVID-19 seroconversion. Fluorophore-labeled SARS-CoV-2 spike receptor-binding domain recombinant protein (F-RBD) was discovered to operate as a bioprobe that emits a strong fluorescence upon COVID-19 antibody detection; however, F-RBD fluorescence was deactivated by graphene oxide-decorated surfaces when COVID-19 antibodies are absent in the sample. With a cost of less than 0.5 USD per test (at laboratory scale), the biosensing system offers optimum results within 42 min. To demonstrate that this technology is technically sound in a relevant environment, 34 human serum samples were analyzed and clearly differentiated, requiring a tiny amount of serum (1 μL to be later diluted in saline buffer).

No abstract

Due its extraordinary optical properties, reduced graphene oxide (rGO) favors the analytical performance in our GO-FRET-based biosensing platform. In this work, we are developing a GO/rGO-based biosensing platform to optimize the sensitivity of this system.